argenx SE (ARGX) Price

Gilead HIV Drug Succeeds In Phase 3 Trial

Gilead Sciences announced its investigational HIV treatment, a combination of bictegravir and lenacapavir (BIC/LEN), met its primary endpoint in a Phase 3 trial, demonstrating non-inferiority to its own market-leading drug, BIKTARVY, for maintaining viral suppression.